drugset / Trial / NCT01540487
Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin
RandomizedCrossoverOpen-labelTreatment
Summary
The aim of the trial is to assess the relative bioavailability of fixed dose combination tablets of linagliptin and metformin compared to the administration of two single tablets (linagliptin and metformin ) in Chinese subjects. The availability of a fixed dose combination tablet is expected to significantly enhance patients' compliance with antidiabetic treatment., in particular with concern to the frequent polypharmacy in diabetic patients.
Timeline
- Start
- 2012-02
- Primary completion
- 2012-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linagliptin | Small molecule | 2.5 mg | Oral |
| Subject | Metformin | Small molecule | 500 mg | Oral |
| Subject | Metformin | Small molecule | 850 mg | Oral |
Indications
No indication recorded.